

Some see slow and steady scientific progress.

We see a revolution.

August 2022



KAI
Living with Duchenne
muscular dystrophy

MED-US-NP-0096

Forward Looking Statements

This presentation contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our opportunities in the rare disease space; market opportunities with respect to our RNA technologies, gene therapy and gene editing; the potential benefits of our technologies and scientific approaches; the potential of our collaborations and partnerships; and expected timelines and milestones.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control and are based on our current beliefs, expectations and assumptions regarding our business. Actual results and financial condition could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties and could materially and adversely affect our business, results of operations and trading price. Potential known risk factors include, among others, the following: our data for our different programs may not be sufficient for obtaining regulatory approval; our product candidates, including those with strategic partners, may not result in viable treatments suitable for commercialization due to a variety of reasons, including the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful; the expected benefits and opportunities related to our agreements with our strategic partners may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreements, challenges and uncertainties inherent in product research and development and manufacturing limitations; we may not be able to execute on our business plans and goals, including meeting our expected or planned regulatory milestones and timelines, clinical development plans, and bringing our product candidates to market, for various reasons including possible limitations of our financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office; and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in its other SEC filings.

For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review Sarepta's filings with the SEC. We caution investors not to place considerable reliance on the forward-looking statements contained in this presentation. The forward-looking statements in this presentation are made as of the date of this presentation only and, other than as required under applicable law, Sarepta does not undertake any obligation to publicly update its forward-looking statements.

SareptAssist Support Program

SareptAssist is a support program that helps patients navigate the process of starting and staying on therapy.

- SareptAssist's patient support program has been helping patients and their care teams navigate the healthcare system for over 5 years
- Dedicated Case Managers have experience in rare diseases (including knowledge of insurance plans and healthcare networks)
- A Case Manager provides one-on-one, personalized support to patients and their caregivers
 - Reimbursement support (BI, PA, reauthorization, appeals)
 - Financial assistance options
 - Treatment logistics/pharmacy coordination
 - Connect you with an Educational Support Manager
 - Connect you with a Patient Access Manager
- Case Managers are available Monday through Friday, from 8:30 AM to 6:30 PM ET

Contact SareptAssist at 1-888-SAREPTA (1-888-727-3782)

<https://www.sarepta.com/sareptassist>

Se habla Español (other language translations available)



FINN

living with Duchenne
and his family

Some see slow and steady scientific progress.

We see a revolution.



KAI
Living with Duchenne
muscular dystrophy

SAREPTA, SAREPTA THERAPEUTICS, the SAREPTA Helix Logo, SAREPTASSIST are trademarks of Sarepta Therapeutics, Inc. registered in the U.S. Patent and Trademark Office and may be registered in various other jurisdictions.